Yuko Palesch to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications Yuko Palesch has written about Clinical Trials, Phase III as Topic.
Connection Strength
1.544
-
Treatment effect on ordinal functional outcome using piecewise multistate Markov model with unobservable baseline: an application to the modified Rankin scale. J Biopharm Stat. 2019; 29(1):82-97.
Score: 0.580
-
Impact of safety monitoring on error probabilities of binary efficacy outcome analyses in large phase III group sequential trials. Pharm Stat. 2012 Jul-Aug; 11(4):310-7.
Score: 0.379
-
Applying a phase II futility study design to therapeutic stroke trials. Stroke. 2005 Nov; 36(11):2410-4.
Score: 0.240
-
Assessing the impact of safety monitoring on the efficacy analysis in large Phase III group sequential trials with non-trivial safety event rate. J Biopharm Stat. 2016; 26(4):672-85.
Score: 0.117
-
Flexible analytical methods for adding a treatment arm mid-study to an ongoing clinical trial. J Biopharm Stat. 2012; 22(4):758-72.
Score: 0.092
-
[Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH)-II at Japan site: study design and advance construction of domestic research network]. Rinsho Shinkeigaku. 2012; 52(9):642-50.
Score: 0.092
-
Evolution of practice during the Interventional Management of Stroke III Trial and implications for ongoing trials. Stroke. 2014 Dec; 45(12):3606-11.
Score: 0.028
-
Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology. 2006 Mar 14; 66(5):628-33.
Score: 0.015